# SLC6A6

## Overview
The SLC6A6 gene encodes the solute carrier family 6 member 6 protein, commonly known as the taurine transporter (TauT). This protein is a transmembrane transporter that plays a critical role in the cellular uptake of taurine, an essential amino acid involved in various physiological processes. As a member of the solute carrier family 6, TauT is characterized by its 12 transmembrane domains, which facilitate the transport of taurine across cell membranes in tissues such as the placenta, retina, and testis (Pramod2013SLC6; Freissmuth2017SLC6). The transporter is integral to maintaining cellular osmoregulation and is implicated in processes such as fetal development, photoreceptor function, and sperm motility (Kubo2016Impact; Kubo2022Involvement; Desforges2013Taurine). Mutations in the SLC6A6 gene have been associated with clinical conditions such as early-onset retinal degeneration and colorectal cancer, highlighting its significance in both normal physiology and disease states (Yasunaga2014Role; Preising2019Biallelic).

## Structure
The SLC6A6 gene encodes the taurine transporter protein, which is part of the solute carrier family 6. This protein is integral to the plasma membrane and is involved in the transport of taurine, an important osmolyte. The primary structure of the SLC6A6 protein consists of amino acid sequences that form 12 transmembrane domains, typical of the SLC6 family transporters (Pramod2013SLC6). These domains are mostly α-helical and display internal pseudosymmetry, with transmembrane segments 6 to 10 being inverted repeats of segments 1 to 5 (Freissmuth2017SLC6).

The secondary structure is characterized by a 5 + 5 helical architecture, where the transmembrane domains form two antiparallel pentahelical bundles (Pramod2013SLC6). The tertiary structure involves the arrangement of these helices within the membrane, forming a substrate binding site with unwound transmembrane segments 1 and 6, along with segments 3 and 8 (Pramod2013SLC6).

The quaternary structure may involve interactions with other proteins or forming homodimers, although specific details on this aspect are not provided in the context. Common post-translational modifications, such as phosphorylation, can regulate the activity of the transporter. Splice variants may result in isoforms with different functional properties, although specific isoforms are not detailed in the provided context.

## Function
The SLC6A6 gene encodes the taurine transporter (TauT), which is crucial for the transport of taurine across cell membranes in various tissues. Taurine is the most abundant amino acid in the human placenta and plays a vital role in fetal development, as the fetus and placenta cannot synthesize it. In the placenta, TauT facilitates the uptake of taurine from maternal blood into the syncytiotrophoblast, which is essential for maintaining normal trophoblast cell turnover and differentiation, crucial for nutrient delivery to the fetus (Desforges2013Taurine).

TauT is also active in the retina, where it maintains high taurine concentrations necessary for photoreceptor development and function. It is expressed in retinal capillary endothelial cells and retinal pigment epithelial cells, contributing to taurine transport at the blood-retinal barrier (Kubo2016Impact; Preising2019Biallelic). In the testis, TauT is involved in taurine transport at the blood-testis barrier, playing a role in protecting sperm from oxidative stress and maintaining sperm motility and count (Kubo2022Involvement).

TauT's function extends to osmoregulation, where it adjusts intracellular solute content to maintain cell volume, and it is implicated in bile acid metabolism in the liver (Pramod2013SLC6).

## Clinical Significance
Mutations in the SLC6A6 gene, which encodes the taurine transporter TAUT, have been linked to early-onset retinal degeneration. Specifically, biallelic mutations, such as the p.A78E variant, result in significantly reduced taurine uptake, leading to decreased taurine levels in plasma, skeletal muscle, and the brain. This deficiency is associated with panretinal degeneration, characterized by severe visual impairment, including reduced visual acuity and color vision, as well as structural changes in the retina (Preising2019Biallelic). The mutation affects the structural stability of the TAUT protein, potentially altering taurine, sodium, and chloride binding sites, which may contribute to the observed clinical manifestations (Preising2019Biallelic).

In addition to retinal degeneration, alterations in SLC6A6 expression have been implicated in colorectal cancer (CRC). The gene is overexpressed in CRC cells, enhancing their survival and contributing to multidrug resistance. Knockdown of SLC6A6 in these cells reduces survival and chemoresistance, suggesting its role in maintaining cancer stem cell-like properties. This makes SLC6A6 a potential target for CRC therapy, as its inhibition could improve treatment outcomes (Yasunaga2014Role).

## Interactions
The SLC6A6 gene encodes the taurine transporter (TauT), which is involved in several protein interactions. One notable interaction is with the Na+/H+ exchanger regulatory factor 1 (NHERF1), encoded by the SLC9A3R1 gene. NHERF1 binds directly to the C-terminal ETMM motif of TauT. This interaction was confirmed through a GST-pull down assay, where NHERF1 was detected as a binding partner to the wild-type TauT C-terminus but not to a deletion mutant lacking the ETMM motif. The interaction between TauT and NHERF1 enhances the transport activity of TauT, as evidenced by increased maximum transport velocity (Vmax) for GABA uptake in Xenopus laevis oocytes co-expressing both proteins, although the affinity (Km) for GABA remains unchanged (Tachikawa2018Assembly).

In the context of the blood-testis barrier, TauT is involved in taurine transport, where it may interact with other transporters such as mGAT3. The presence of TauT in the testis and its role in taurine uptake was demonstrated through various assays, including knockdown experiments that showed a significant reduction in taurine uptake when TauT expression was decreased (Kubo2022Involvement).


## References


[1. (Yasunaga2014Role) Masahiro Yasunaga and Yasuhiro Matsumura. Role of slc6a6 in promoting the survival and multidrug resistance of colorectal cancer. Scientific Reports, April 2014. URL: http://dx.doi.org/10.1038/srep04852, doi:10.1038/srep04852. This article has 39 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep04852)

[2. (Kubo2022Involvement) Yoshiyuki Kubo, Sakiko Ishizuka, Takeru Ito, Daisuke Yoneyama, Shin-ichi Akanuma, and Ken-ichi Hosoya. Involvement of taut/slc6a6 in taurine transport at the blood–testis barrier. Metabolites, 12(1):66, January 2022. URL: http://dx.doi.org/10.3390/metabo12010066, doi:10.3390/metabo12010066. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/metabo12010066)

[3. (Desforges2013Taurine) M Desforges, L Parsons, M Westwood, C P Sibley, and S L Greenwood. Taurine transport in human placental trophoblast is important for regulation of cell differentiation and survival. Cell Death &amp; Disease, 4(3):e559–e559, March 2013. URL: http://dx.doi.org/10.1038/cddis.2013.81, doi:10.1038/cddis.2013.81. This article has 38 citations.](https://doi.org/10.1038/cddis.2013.81)

[4. (Kubo2016Impact) Yoshiyuki Kubo, Shin-ichi Akanuma, and Ken-ichi Hosoya. Impact of slc6a transporters in physiological taurine transport at the blood–retinal barrier and in the liver. Biological and Pharmaceutical Bulletin, 39(12):1903–1911, 2016. URL: http://dx.doi.org/10.1248/BPB.B16-00597, doi:10.1248/bpb.b16-00597. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.1248/BPB.B16-00597)

[5. (Tachikawa2018Assembly) Masanori Tachikawa, Reiji Yokoyama, Shin-ichi Akanuma, and Ken-ichi Hosoya. Assembly of taurine transporter (slc6a6) with na&lt;sup&gt;+&lt;/sup&gt;–h&lt;sup&gt;+&lt;/sup&gt; exchanger regulatory factor 1 (slc9a3r1) improves gaba transport activity by increasing the maximum transport velocity. Biological and Pharmaceutical Bulletin, 41(3):338–341, 2018. URL: http://dx.doi.org/10.1248/bpb.b17-00664, doi:10.1248/bpb.b17-00664. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1248/bpb.b17-00664)

[6. (Pramod2013SLC6) Akula Bala Pramod, James Foster, Lucia Carvelli, and L. Keith Henry. Slc6 transporters: structure, function, regulation, disease association and therapeutics. Molecular Aspects of Medicine, 34(2–3):197–219, April 2013. URL: http://dx.doi.org/10.1016/j.mam.2012.07.002, doi:10.1016/j.mam.2012.07.002. This article has 233 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.mam.2012.07.002)

[7. (Freissmuth2017SLC6) Michael Freissmuth, Thomas Stockner, and Sonja Sucic. SLC6 Transporter Folding Diseases and Pharmacochaperoning, pages 249–270. Springer International Publishing, 2017. URL: http://dx.doi.org/10.1007/164_2017_71, doi:10.1007/164_2017_71. This article has 29 citations.](https://doi.org/10.1007/164_2017_71)

[8. (Preising2019Biallelic) Markus N. Preising, Boris Görg, Christoph Friedburg, Natalia Qvartskhava, Birgit S. Budde, Michele Bonus, Mohammad R. Toliat, Christopher Pfleger, Janine Altmüller, Diran Herebian, Mila Beyer, Helge J. Zöllner, Hans-Jörg Wittsack, Jörg Schaper, Dirk Klee, Ulrich Zechner, Peter Nürnberg, Jörg Schipper, Alfons Schnitzler, Holger Gohlke, Birgit Lorenz, Dieter Häussinger, and Hanno J. Bolz. Biallelic mutation of human slc6a6 encoding the taurine transporter taut is linked to early retinal degeneration. The FASEB Journal, 33(10):11507–11527, July 2019. URL: http://dx.doi.org/10.1096/fj.201900914rr, doi:10.1096/fj.201900914rr. This article has 39 citations.](https://doi.org/10.1096/fj.201900914rr)